Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 8314 results

  1. Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

    Health technology evaluations
    In development

  2. Asunercept for treating glioblastoma [1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development Reference number: GID-TA10623 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  6. Efzimfotase alfa for treating hypophosphatasia in people 12 years and over [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. UX111 for treating mucopolysaccharidosis type IIIA [ID6540]

    Awaiting development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development

  12. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date: TBC

    NICE guideline
    In development

  13. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development